COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in PregnancyObservational Study Published on 2022-07-012022-10-04 Journal: Pharmacoepidemiology and drug safety [Category] COVID19(2023년), SARS, 임상, [키워드] antibody Anticoagulant chloroquine/hydroxychloroquine country COVID-19 COVID-19 patient COVID-19 test COVID-19 therapeutics COVID-19 treatment demographic characteristics drug drug utilization enrolled exposure finding Health include increased risk infected with SARS-CoV-2 information interferon International medications Mild moderate MOST Neonatal Observational cohort study Obstetric online questionnaire oseltamivir outcome outcomes participant pattern pharmacoepidemiology Pregnancy pregnant pregnant women Preterm birth registry Remdesivir reported repurposed therapy risk safety profile severe cases steroid Symptoms Therapies therapy treat with COVID-19 women [DOI] 10.1002/pds.5440 PMC 바로가기 [Article Type] Observational Study
Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatmentsMethodology Published on 2022-01-202022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] acute illness approach average Care clinical information clinical trials Community complications contributing to COVID-19 COVID-19 pandemic data data-driven Department development ENhance enrolment EudraCT Evidence healthcare high risk information Innovation IRAS ISRCTN methodology National NHS Older participant Participants Patient platform Platform trial Positive test positive test result primary care provided Public and patient involvement and engagement raised randomisation REC receiving Record recruit recruitment reduced Registered repurposed therapy required Research Result Safe SCR Standard supplementary material Test therapeutic trace Treatment Trial trial participant unique was used [DOI] 10.1186/s13063-021-05965-4 PMC 바로가기 [Article Type] Methodology
Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date중요하지 않은 COVID-19 폐렴 치료를 위한 토실리주맙: 현재까지의 근거 및 임상 증거 개요Review Published on 2021-10-012022-09-11 Journal: Expert review of clinical pharmacology [Category] MERS, SARS, 진단, 치료제, [키워드] Area benefit Clinical deterioration clinical evidence clinical trial clinical trials concomitant treatments COVID-19 COVID-19 pneumonia cytokine cytokine release Cytokine release syndrome Evidence expert Guidance immunomodulatory immunomodulatory therapy implication in some interleukin interleukin-6 investigated other disease other diseases pandemic pathophysiology patient selection patients with COVID-19 Physiology Pneumonia question rationale repurposed therapy systemic inflammation Tocilizumab Treatment [DOI] 10.1080/17512433.2021.1949286 PMC 바로가기 [Article Type] Review
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19Immunology Published on 2020-08-112022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] additional treatment option Affect Biomedical research Comorbidities Comorbidity condition conditions COVID-19 COVID-19 in patient COVID-19 progression demonstrated drug etiology exacerbate global healthcare greater immune dysfunction immune system Immunology and infectious diseases Impact individual Inflammation Inflammatory diseases limit outbreak progression repurposed therapy Respiratory disease risk SARS-CoV-2 SARS-COV-2 infection therapy treat Treatment turn underlying disease virus immunity [DOI] 10.3389/fimmu.2020.01991 PMC 바로가기 [Article Type] Immunology